EUVIMEDEUVIMED entdecken
Crossref

Restoring Brain Function in Autism: GSK3β Inhibition by 6-Bromoindirubin-3′-oxime Reverses Valproic Acid-induced Neuropathology

Ashish Jain iD, Neha Dhir, Praisy K Prabha, Anupam Raja, Amit Raj Sharma iD, Tamanna Kaundal, Shiv Charan, Harvinder Singh iD, Rubal Singla, Deepti Malik, Alka Bhatia iD, Dibyajyoti Banerjee und 5 weitere

ACS Chemical Neuroscience · 2025

DOI: 10.1021/acschemneuro.5c00125 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Chemical Neuroscience, 2025. Verfasst von Ashish Jain und 16 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Pharmacology Laboratory (EPL), Neurobehavioral Research Laboratory (NBRL), Department of Pharmacology, Postgraduate Institute of Medical…. Hauptthemen laut MEDLINE: Glycogen Synthase Kinase 3 beta, Oximes, Indoles, Valproic Acid. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 164 Literaturangaben. Gefördert von: Indian Council of Medical Research, Science and Engineering Research Board.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autism spectrum disorder (ASD) is a complex neurodevelopmental condition characterized by social deficits, restricted interests, and repetitive behaviors. Although aripiprazole and risperidone are FDA-approved for ASD, they primarily target comorbid symptoms and are associated with significant side effects. This study aimed to investigate the effects of 6-bromoindirubin-3'-oxime (6BIO), a glycogen synthase kinase 3β (GSK3β) inhibitor, in a VPA model of ASD. Pregnant Wistar rat dams received a single intraperitoneal (ip) injection of VPA (600 mg/kg) or an equal volume of saline on GD 12.5. Offspring prenatally exposed to VPA showed impairments in early age observations, such as nervous reflex, motor coordination, sensory function, and developmental milestones. On postnatal day (PND), 23 male and female offspring were separated and randomly assigned to receive either risperidone (2.5 mg/kg, po) or 6BIO (15 or 30 μg/kg, ip) daily until PND 82. Systemic postnatal administration of 6BIO dose-dependently ameliorated anxiety-like behavior, exploratory, social deficit, repetitive behavior, spatial cognition, recognition memory, motor coordination, gastrointestinal motility, brain edema, and blood-brain barrier functions. Furthermore, chronic 6BIO postnatal treatment significantly attenuated VPA-induced neuronal damage in the prefrontal cortex, hippocampus, and cerebellum. 6BIO also significantly suppressed the upregulated cytosolic GSK3β phosphorylation, as determined by immunohistochemistry and Western blotting. Additionally, 6BIO modulated mRNA expression levels of Wnt, CHD8, SHANK3, GAD65, and 67, and transcriptional factors such as β-catenin and NLGN3 were altered by prenatal VPA exposure. In conclusion, these findings suggest that 6BIO may exert neuroprotective effects via GSK3β inhibition, indicating its potential as a candidate compound for therapeutic intervention in ASD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycogen Synthase Kinase 3 betaOximesIndolesValproic AcidBrainAutistic DisorderAutism Spectrum DisorderAnimalsRats, WistarFemaleMalePregnancyRatsPrenatal Exposure Delayed EffectsDisease Models, AnimalRisperidone

Stichwörter der Autor:innen

6BIOGSK3βWistar ratsautism spectrum disorderneuromodulatory therapeuticstranscriptional regulationvalproic acid

Substanzen

Glycogen Synthase Kinase 3 betaOximesIndolesValproic Acid6-bromoindirubin-3'-oximeRisperidone

Autor:innen und Institutionen

  • Experimental Pharmacology Laboratory (EPL), Neurobehavioral Research Laboratory (NBRL), Department of Pharmacology, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India.
  • Department of Neurology, PGIMER, Chandigarh 160012, India.
  • Department of Biochemistry, All India Institute of Medical Sciences (AIIMS) Bilaspur, Bilaspur, Himachal Pradesh 174037, India.
  • Department of Experimental Medicine and Biotechnology, PGIMER, Chandigarh 160012, India.
  • Department of Immunopathology, PGIMER, Chandigarh 160012, India.
  • Department of Biochemistry, PGIMER, Chandigarh 160012, India.

ORCID-Profile: Ashish Jain, Amit Raj Sharma, Harvinder Singh, Alka Bhatia, Bikash Medhi, Ajay Prakash

Förderung

  • Indian Council of Medical Research
  • Science and Engineering Research Board

Zitieren

APA

Jain, A., Dhir, N., Prabha, P. K., Raja, A., Sharma, A. R., Kaundal, T., Charan, S., Singh, H., Singla, R., Malik, D., Bhatia, A., Banerjee, D., Saikia, B., Zohmangaihi, D., Goyal, M. K., Medhi, B., & Prakash, A. (2025). Restoring Brain Function in Autism: GSK3β Inhibition by 6-Bromoindirubin-3′-oxime Reverses Valproic Acid-induced Neuropathology. ACS Chemical Neuroscience. https://doi.org/10.1021/acschemneuro.5c00125

Vancouver

Jain A, Dhir N, Prabha PK, Raja A, Sharma AR, Kaundal T, et al. Restoring Brain Function in Autism: GSK3β Inhibition by 6-Bromoindirubin-3′-oxime Reverses Valproic Acid-induced Neuropathology. ACS Chemical Neuroscience. 2025. doi:10.1021/acschemneuro.5c00125

BibTeX
@article{Jain2025,
  author = {Jain, Ashish and Dhir, Neha and Prabha, Praisy K and Raja, Anupam and Sharma, Amit Raj and Kaundal, Tamanna and Charan, Shiv and Singh, Harvinder and Singla, Rubal and Malik, Deepti and Bhatia, Alka and Banerjee, Dibyajyoti and Saikia, Biman and Zohmangaihi, Deepy and Goyal, Manoj K and Medhi, Bikash and Prakash, Ajay},
  title = {Restoring Brain Function in Autism: GSK3β Inhibition by 6-Bromoindirubin-3′-oxime Reverses Valproic Acid-induced Neuropathology},
  journal = {ACS Chemical Neuroscience},
  year = {2025},
  doi = {10.1021/acschemneuro.5c00125}
}
Kostenlos starten →